|
1
|
Wollein U, Schramek N. Simultaneous determination of alkyl mesilates and alkyl besilates in finished drug products by direct injection GC/MS. Eur J Pharm Sci 2012; 45:201-4. [DOI: 10.1016/j.ejps.2011.11.008] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2011] [Revised: 09/19/2011] [Accepted: 11/09/2011] [Indexed: 11/29/2022]
|
|
2
|
Cimarosti Z, Giubellina N, Stabile P, Laval G, Tinazzi F, Maton W, Pachera R, Russo P, Moretti R, Rossi S, Cooke JWB, Westerduin P. Route Selection and Process Development for a 5-Piperazinylquinaldine Derivative for the Treatment of Depression and Anxiety. Org Process Res Dev 2011. [DOI: 10.1021/op200140v] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Zadeo Cimarosti
- Chemical Development, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Nicola Giubellina
- Chemical Development, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Paolo Stabile
- Chemical Development, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Gilles Laval
- Chemical Development, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Francesco Tinazzi
- Chemical Development, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - William Maton
- Chemical Development, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Roberta Pachera
- Chemical Development, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Paola Russo
- Chemical Development, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Ramona Moretti
- Chemical Development, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Sara Rossi
- Chemical Development, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Jason W. B. Cooke
- Chemical Development, Medicines Research Centre, GlaxoSmithKline, Stevenage, U.K
| | - Pieter Westerduin
- Chemical Development, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| |
Collapse
|
|
3
|
Snodin DJ. Genotoxic Impurities: A Regulatory Toxicology Commentary on Recent Articles in Organic Process Research & Development. Org Process Res Dev 2011. [DOI: 10.1021/op200205b] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- David J Snodin
- Xiphora Biopharma Consulting, 9 Richmond Apartments, Redland Court Road, Bristol, BS6 7BG U.K
| |
Collapse
|
|
4
|
Giordani A, Kobel W, Gally HU. Overall impact of the regulatory requirements for genotoxic impurities on the drug development process. Eur J Pharm Sci 2011; 43:1-15. [PMID: 21420491 DOI: 10.1016/j.ejps.2011.03.004] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2010] [Revised: 01/18/2011] [Accepted: 03/05/2011] [Indexed: 11/19/2022]
Abstract
In the last decade a considerable effort has been made both by the regulators and the pharmaceutical industry to assess genotoxic impurities (GTI) in pharmaceutical products. Though the control of impurities in drug substances and products is a well established and consolidated procedure, its extension to GTI has given rise to a number of problems, both in terms of setting the limits and detecting these impurities in pharmaceutical products. Several papers have dealt with this issue, discussing available regulations, providing strategies to evaluate the genotoxic potential of chemical substances, and trying to address the analytical challenge of detecting GTI at trace levels. In this review we would like to discuss the available regulations, the toxicological background for establishing limits, as well as the analytical approaches used for GTI assessment. The final aim is that of providing a complete overview of the topic with updated available information, to address the overall GTI issue during the development of new drug substances.
Collapse
|